Similar articles for PMID: 32620605

Year	Number of Results
2003	1
2007	2
2010	1
2011	5
2012	5
2013	3
2014	4
2015	5
2016	6
2017	11
2018	29
2019	30
2020	40
2021	42
2022	32
2023	14
2024	0

1

FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines.

Begg SKS, Birnbaum DJ, Clark JW, Mino-Kenudson M, Wellner UF, Schilling O, Lillemoe KD, Warshaw AL, Castillo CF, Liss AS. Begg SKS, et al. Anticancer Res. 2020 Jul;40(7):3659-3667. doi: 10.21873/anticanres.14355. Anticancer Res. 2020. PMID: 32620605

2

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.

Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V; German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Kunzmann V, et al. Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33338442 Clinical Trial.

3

Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.

Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Perri G, et al. JAMA Surg. 2020 Sep 1;155(9):832-839. doi: 10.1001/jamasurg.2020.2286. JAMA Surg. 2020. PMID: 32667641 Free PMC article.

4

Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Stainthorpe A, Greenhalgh J, Bagust A, Richardson M, Boland A, Beale S, Duarte R, Kotas E, Banks L, Palmer D. Stainthorpe A, et al. Pharmacoeconomics. 2018 Oct;36(10):1153-1163. doi: 10.1007/s40273-018-0646-1. Pharmacoeconomics. 2018. PMID: 29600384 Free PMC article. Review.

5

Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.

Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I. Baron MK, et al. Pancreas. 2021 Jul 1;50(6):796-802. doi: 10.1097/MPA.0000000000001844. Pancreas. 2021. PMID: 34347727

6

Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.

Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, Moik F, Barth DA, Rossmann CH, Stotz M, Schaberl-Moser R, Pichler M, Stöger H, Greil R, Djanani A, Schlick K, Gerger A. Riedl JM, et al. Eur J Cancer. 2021 Jul;151:3-13. doi: 10.1016/j.ejca.2021.03.040. Epub 2021 May 2. Eur J Cancer. 2021. PMID: 33951545 Free article.

7

Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.

Ellenrieder V, König A, Seufferlein T. Ellenrieder V, et al. Digestion. 2016;94(1):44-9. doi: 10.1159/000447739. Epub 2016 Jul 21. Digestion. 2016. PMID: 27438590 Review.

8

Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.

Surinach A, Phung T, Abdul-Rahim O, Khushman M. Surinach A, et al. Curr Oncol. 2020 Apr;27(2):e222-e225. doi: 10.3747/co.27.5893. Epub 2020 May 1. Curr Oncol. 2020. PMID: 32489272 Free PMC article.

9

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.

Sams L, Kruger S, Heinemann V, Bararia D, Haebe S, Alig S, Haas M, Zhang D, Westphalen CB, Ormanns S, Metzger P, Werner J, Weigert O, von Bergwelt-Baildon M, Rataj F, Kobold S, Boeck S. Sams L, et al. Clin Transl Oncol. 2021 Nov;23(11):2394-2401. doi: 10.1007/s12094-021-02620-x. Epub 2021 Apr 19. Clin Transl Oncol. 2021. PMID: 33876417 Free PMC article.

10

A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.

Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS, Shan YS, Chen LT. Chiang NJ, et al. Eur J Cancer. 2020 Jan;124:123-130. doi: 10.1016/j.ejca.2019.10.023. Epub 2019 Nov 22. Eur J Cancer. 2020. PMID: 31765987 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

196 results

Results by year